SLC5A2 and type 1 diabetes mellitus: Currently, there are a number of SGLT2 inhibitors that are under development or in clinical trials.[6–8] Prior meta-analyses had established the safety and efficacy of SGLT2 inhibitors in T1DM, but with low level of evidences and inconsistent conclusions.[9,10] However, recently, many new RCTs has been published, we hence try to design a study protocol to assess the effect of SGLT2 inhibitors on cardiovascular events via a comprehensive meta-analysis of data from much more RCTs, including sensitivity and subgroup analyses.